- Investigator
- Mohammad Ilyas
- Ages
- 0 Years - 12 Years
- Sexes
- All
Clinical trials
-
Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children under 12 Years of Age with Hyperkalaemia -
Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Patients Hospitalized for Viral Lung Infection Requiring Supplemental Oxygen - Investigator
- Tracy T Ashby
- Ages
- 18 Years - NA Years
- Sexes
- All
-
Switching from Clopidogrel to Low-dose Prasugrel in Patients at Dual-risk Following Percutaneous Coronary Intervention: TAILOR-BLEED-2 study - Investigators
- Dominick J Angiolillo, Luis G Ortega Paz
- Ages
- 18 Years - 99 Years
- Sexes
- All
-
STOMP study - Investigator
- Mobeen H Rathore
- Ages
- 7 Years - 60 Years
- Sexes
- All
-
The MAGICAL SV Randomized Clinical Trial - Investigator
- Daniel E Soffer
- Ages
- 18 Years - 99 Years
- Sexes
- All
-
Safety of Sildenafil in Premature Infants at Risk of Bronchopulmonary Dysplasia (20180529) - Investigators
- Mark Hudak, William R Driscoll, Ma Ingyinn, Padma S Nandula, Sanket Shah, Renu Sharma, Winston T Sheen, Shalinkumar P Patel, Orlyn C Lavilla, John W Logan, Dawn D McDaniel
- Ages
- N/A
- Sexes
- All
-
A Phase 2/3, Randomized, Controlled, Masked, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Two Doses of AGTC-501, a Recombinant Adeno-associated Virus Vector Expressing RPGR (rAAV2tYF-GRK1-RPGR), Compared to an Untreated Control - Investigator
- Sandeep Grover
- Ages
- 12 Years - 50 Years
- Sexes
- Male
-
RECOVER-ENERGIZE: A Platform Protocol for Evaluation of Interventions for Exercise Intolerance in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) - Investigators
- Carmen Isache, Jorge L Verdecia
- Ages
- 18 Years - 80 Years
- Sexes
- All
-
Use of AC through Provider Prompting about Oral AC Therapy for AF (SUPPORT-AF) IV - Investigator
- Luis G Ortega Paz
- Ages
- 18 Years - 99 Years
- Sexes
- All
-
Phase III, randomized, double-blind, placebo-controlled study to assess BI 1291583 2.5 mg once daily for up to 76 weeks in patients with bronchiectasis - Investigator
- Michael D Schweitzer Barrios
- Ages
- 18 Years - 99 Years
- Sexes
- All